M&A Deal Summary

Boston Scientific Acquires Bard EP

On June 28, 2013, Boston Scientific acquired medical products company Bard EP from C. R. Bard for 275M USD

Acquisition Highlights
  • This is Boston Scientific’s 17th transaction in the Medical Products sector.
  • This is Boston Scientific’s 17th largest (disclosed) transaction.
  • This is Boston Scientific’s 22nd transaction in the United States.
  • This is Boston Scientific’s 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2013-06-28
Target Bard EP
Sector Medical Products
Buyer(s) Boston Scientific
Sellers(s) C. R. Bard
Deal Type Divestiture
Deal Value 275M USD

Target

Bard EP

Lowell, Massachusetts, United States
website
Bard EP offers a comprehensive portfolio including advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boston Scientific

Marlborough, Massachusetts, United States

website

Category Company
Founded 1979
Sector Medical Products
Employees45,000
Revenue 12.7B USD (2022)
DESCRIPTION
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.

Boston Scientific is a medical technology company. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 26 of 62
Sector (Medical Products) 17 of 48
Type (Divestiture) 2 of 10
State (Massachusetts) 3 of 5
Country (United States) 22 of 47
Year (2013) 2 of 2
Size (of disclosed) 17 of 32
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-04-15 Anulex Technologies - FiXate Tissue Band

United States

Anulex Technologies - FiXate Tissue Band is a novel suturing device that is designed to enable quick and simple placement of a suture to help secure a spinal cord stimulator (SCS) lead or pain pump catheter.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-06 IoGyn

Cupertino, California, United States

IoGyn is a medical device start-up located in Cupertino, California focused on the development of safe and effective products for minimally-invasive gynecological surgery. IoGyn has developed and received U.S. Food and Drug Administration (FDA) clearance for the Symphion™ System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps.

Buy $65M

Seller(S) 1

SELLER

C. R. Bard

Murray Hill, New Jersey, United States

website

Category Company
Founded 1907
Sector Medical Products
Employees14,900
Revenue 3.7B USD (2016)
DESCRIPTION
Entrance to C. R. Bard's corporate headquarters in Murray Hill, New Jersey.
Entrance to C. R. Bard's corporate headquarters in Murray Hill, New Jersey.

C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-12-20 Lutonix

New Hope, Minnesota, United States

Lutonix, Inc., delivers an optimal therapeutic dose of paclitaxel to stenosed peripheral and coronary vessels via a standard angioplasty balloon.

Buy $225M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-19 Medafor

Minneapolis, Minnesota, United States

Medafor, Inc., is a developer and supplier of plant based hemostatic agents. Medafor develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles.

Buy $200M
Mergr

Product

Company

Legal